BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
-7.91%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$118M
AUM Growth
+$118M
(-12%)
Cap. Flow
-$12.1M
Cap. Flow
% of AUM
-10.3%
Top 10 Holdings %
Top 10 Hldgs %
75.47%
Holding
54
New
–
Increased
13
Reduced
5
Closed
3
Top Buys
| 1 |
Axogen
AXGN
|
$665K |
| 2 |
Prothena Corp
PRTA
|
$650K |
| 3 |
BLUE
bluebird bio
BLUE
|
$626K |
| 4 |
Biodesix
BDSX
|
$504K |
| 5 |
Karyopharm Therapeutics
KPTI
|
$376K |
Top Sells
| 1 |
AXDX
Accelerate Diagnostics
AXDX
|
$11.7M |
| 2 |
Soleno Therapeutics
SLNO
|
$1.05M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$984K |
| 4 |
United Therapeutics
UTHR
|
$903K |
| 5 |
Neurocrine Biosciences
NBIX
|
$788K |
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Energy | 5.2% |
| 3 | Consumer Staples | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $41.6M | 35.32% | 716,297 -12,288 | -2% | -$713K |
|
|
2
Biodesix
BDSX
$62.6M
| $8.74M | 7.43% | 5,348,273 +308,640 | +6% | +$504K |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $8.69M | 7.38% | 77,240 -7,000 | -8% | -$788K |
|
|
4
Prothena Corp
PRTA
$441M
| $8.18M | 6.95% | 169,574 +13,463 | +9% | +$650K |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $5.01M | 4.26% | 240,400 -9,000 | -4% | -$188K |
|
6
QuidelOrtho
QDEL
$1.95B
| $4.76M | 4.05% | 65,203 | – | – |
|
7
Ovintiv
OVV
$10.8B
| $4.01M | 3.4% | 84,200 | – | – |
|
|
IMGN
8
DELISTED
Immunogen Inc
IMGN
| $3.02M | 2.56% | 190,000 | – | – |
|
|
9
United Therapeutics
UTHR
$13.8B
| $2.48M | 2.11% | 11,000 -4,000 | -27% | -$903K |
|
10
Elutia
ELUT
$96.7M
| $2.37M | 2.01% | 1,655,184 | – | – |
|
11
Harrow
HROW
$1.44B
| $2.16M | 1.83% | 150,000 | – | – |
|
12
Phreesia
PHR
$1.88B
| $1.54M | 1.31% | 82,700 | – | – |
|
13
Alkermes
ALKS
$4.78B
| $1.4M | 1.19% | 50,000 | – | – |
|
|
BLUE
14
DELISTED
bluebird bio
BLUE
| $1.38M | 1.18% | 455,200 +206,000 | +83% | +$626K |
|
15
Corcept Therapeutics
CORT
$7.35B
| $1.36M | 1.16% | 50,000 | – | – |
|
16
Masimo
MASI
$7.59B
| $1.34M | 1.14% | 15,280 | – | – |
|
17
Foghorn Therapeutics
FHTX
$286M
| $1.32M | 1.13% | 264,843 | – | – |
|
|
AXDX
18
DELISTED
Accelerate Diagnostics
AXDX
| $1.3M | 1.1% | 225,239 -2,027,149 | -90% | -$11.7M |
|
|
INBX
19
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $1.29M | 1.1% | 70,448 | – | – |
|
|
ETRN
20
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $1.25M | 1.06% | 133,050 | – | – |
|
21
Alphatec Holdings
ATEC
$2.35B
| $1.04M | 0.88% | 80,000 | – | – |
|
22
Ventyx Biosciences
VTYX
$171M
| $917K | 0.78% | 26,400 | – | – |
|
|
PXD
23
DELISTED
Pioneer Natural Resource Co.
PXD
| $872K | 0.74% | 3,800 | – | – |
|
24
10x Genomics
TXG
$1.74B
| $866K | 0.74% | 21,000 +9,000 | +75% | +$371K |
|
|
25
Axogen
AXGN
$743M
| $865K | 0.73% | 173,000 +133,000 | +333% | +$665K |
|